Earli

Earli

Turning Cancer Against Itself.

Founded 2018

Redwood City, United States 36 employees Total: $59.50M Biotechnology, Health Care

Earli mission is to make cancer a benign experience by turning cancer against itself. Earli creates genetic constructs that turn on only in cancer cells and then re-program the cancer cells to produce their own therapies, to kill themselves. Earli has been funded by Andreessen Horowitz's a16z Bio+Health Fund, Khosla Ventures, Perceptive Advisors, Sands Capital, Marc Benioff, Menlo Ventures, Accenture Ventures, Han River Partners (S Korea). Earli is based in Redwood City, California. For decades, the vision has been dreamed about to one day “program disease cells to kill or cure themselves.” If disease cells could be taken control of, they could be forced to run “injected biologic programs” to attack themselves or activate the body’s immune system to fight the disease. Standing in the way is a fundamental unsolved questions in medicine: how to correctly distinguish healthy cells from disease cells. For cancer, many attempts have been made to “kill the bad cells while not killing the good ones.” The conventional approaches are still crude; they attack both cancers and patients, or don't produce any response at all. Earli turns the approach to targeting cancer cells on its head. Based on original research at Stanford University and subsequent 7 years of research at Earli, the company has built programmable genetic constructs that can infiltrate any cells but use conditional logic inside the cell nucleus to determine if a cell is a cancer cell, or not. The construct switches on only in cancer cells, then forcing them to become "factories" that produce encoded proteins that activate the immune system to attack and ultimately kill the cancer. In essence, the cancer cells are forced to produce their own therapies.

Funding Stage	Amount	Investors	Lead Investors	Date
Early VC	Undisclosed	1	GLIN Impact Capital	01 Oct 2024
Series A	$40.00M	8	Casdin Capital, Khosla Ventures +6	01 Jan 2021
Seed	$19.50M	3	ZhenFund, Andreessen Horowitz/ a16z +1	01 Sep 2018
Spinout	Undisclosed	1	Stanford University	01 Jun 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Early VC

Undisclosed

GLIN Impact Capital

01 Oct 2024

Series A

$40.00M

Casdin Capital, Khosla Ventures +6

01 Jan 2021

Seed

$19.50M

ZhenFund, Andreessen Horowitz/ a16z +1

01 Sep 2018

Spinout

Undisclosed

Stanford University

01 Jun 2018

FAQ About Earli

Turning Cancer Against Itself.

Earli was founded in 2018.

Earli is headquartered in Redwood City, United States.

Earli operates in Biotechnology and Health Care.

Earli has approximately 36 employees.

Earli has completed 4 funding rounds, raising a total of $59.50M.

Top alternatives and competitors to Earli include TransCode Therapeutics, Inc., Tango Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Earli and TransCode Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Earli

Funding Rounds & Investors (4)

Earli Alternatives & Competitors

FAQ About Earli